4//SEC Filing
LYONS GARY A 4
Accession 0001415889-24-024795
CIK 0001438533other
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 7:15 PM ET
Size
11.2 KB
Accession
0001415889-24-024795
Insider Transaction Report
Form 4
LYONS GARY A
Director
Transactions
- Exercise/Conversion
Common Stock
2024-10-04$10.48/sh+40,000$419,200→ 91,000 total - Sale
Common Stock
2024-10-04$14.35/sh−21,179$303,874→ 69,821 total - Sale
Common Stock
2024-10-04$15.15/sh−18,821$285,227→ 51,000 total - Exercise/Conversion
Stock option (right to buy)
2024-10-04+40,000→ 0 totalExercise: $10.48Exp: 2024-10-08→ Common Stock (40,000 underlying)
Footnotes (4)
- [F1]This sale was made pursuant to a written plan adopted on March 16, 2023 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024.
- [F2]The weighted average sale price for the transaction reported was $14.3479, and the range of prices were between $13.92 and $14.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]The weighted average sale price for the transaction reported was $15.1547, and the range of prices were between $14.92 and $15.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F4]The stock option is fully vested and exercisable.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001123343
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 7:15 PM ET
- Size
- 11.2 KB